A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) (NCT07533006)
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last approximately 48 weeks, including screening.
Who can join: Review the eligibility criteria below.
Location: Center For Dermatology Clinical Research, Inc. β Fremont, California
Age range: 18 Years to 50 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Center For Dermatology Clinical Research, Inc. β Fremont, California
- Northridge Clinical Trials β Northridge, California
- Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway β Santa Clarita, California
- Health Clinical Research, LLC β Cutler Bay, Florida
- Brigham and Women's Hospital β Boston, Massachusetts
- Revival Research Institute, LLC β Troy, Michigan
- Stracskin β Portsmouth, New Hampshire
- Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue β San Antonio, Texas
- Jordan Valley Dermatology & Research Center β South Jordan, Utah
- Kelowna Health and Memory Centre β Kelowna,
- Ryan Clinical Research Inc. β Newmarket,
- Dar Clinical Research - Ottawa - Hunt Club Road β Ottawa,
- SIMa Recherche β Verdun,
- Beijing Friendship Hospital Affiliate of Capital University β Beijing,
- Huashan Hospital, Fudan University β Shanghai,
- Shanghai Skin Disease Hospital β Shanghai,
- Tianjin Medical University General Hospital β Tianjin,
- Erasmus Medisch Centrum β Rotterdam,
- Centrum Badan Klinicznych PI-House sp. z o.o. β Gdansk,
- Diamond Clinic β Krakow,
- Dermedic Jacek Zdybski β Ostrowiec ΕwiΔtokrzyski,
- Centrum Medyczne Ginemedica β Wroclaw,
- Chung-Ang University Hospital β Dongjak-gu,
- Inha University Hospital β Incheon,
- Jeonbuk National University Hospital β Jeonju,
π Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alopecia Areata
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata β Birmingham, Alabama
- A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo β Northridge, California
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) β Northridge, California
- Alopecia Areata Registry β San Francisco, California
- Intralesional Cyclosporine for Alopecia Areata β Sacramento, California
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) β Scottsdale, Arizona
Explore by condition: All Alopecia Areata clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.